AstraZeneca | AZN - Sales Revenues

AstraZeneca reported $12.02B in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
AbbVie USD 14.3B 374M Dec/2023
Alcon AG USD 2.35B 23M Dec/2023
Almirall EUR 428.46M 37.6M Dec/2023
Amgen USD 8.2B 1.29B Dec/2023
argenx SE USD 417.84M 78M Dec/2023
AstraZeneca USD 12.02B 532M Dec/2023
Bayer EUR 11.86B 1.52B Dec/2023
Biogen USD 2.29B 96.3M Mar/2024
Bristol-Myers Squibb USD 11.9B 423M Mar/2024
Eli Lilly USD 9.35B 145.2M Dec/2023
Fresenius EUR 5.68B 160M Dec/2023
Fresenius Medical Care EUR 4.99B 52M Dec/2023
Galapagos EUR 136.34M 29.08M Sep/2023
Genmab DKK 4.68B 66M Dec/2023
Gilead Sciences USD 7.12B 64M Dec/2023
GlaxoSmithKline GBP 8.05B 95M Dec/2023
GRIFOLS EUR 1.77B 172.07M Dec/2023
Haleon 2.77B 32M Dec/2023
Hikma Pharmaceutical USD 1.45B 21M Dec/2023
Lonza CHF 3.64B 561M Dec/2023
Merck EUR 14.76B 9.54B Mar/2024
Merck USD 15.8B 1.17B Mar/2024
Novartis USD 11.83B 54M Mar/2024
Orion EUR 308.5M 12.6M Mar/2024
Pfizer USD 14.25B 1.02B Dec/2023
Philips EUR 5.06B 591M Dec/2023
Recordati EUR 526.13M 14.22M Dec/2023
Regeneron Pharmaceuticals USD 3.43B 71.6M Dec/2023
Roche Holding CHF 28.94B 842M Dec/2023
Sanofi EUR 10.92B 1.05B Dec/2023
UCB EUR 2.66B 74M Dec/2023